Delta-Fly Pharma

Focus: Delta-Fly Pharma is a Japan-based oncology-focused pharmaceutical company developing early-stage cancer therapeutics, currently operating at a pre-commercial scale with an early-stage pipeline.

Oncology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Delta-Fly Pharma

AI assessmentNot Hiring

No open roles listed right now. Follow Delta-Fly Pharma to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Mid-stage

1 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

DFP-14927

Solid Tumor

Phase 1

Clinical Trials (1)

NCT03943004Trial of DFP-14927 in Advanced Solid Tumors

Phase 1

Help build intelligence for Delta-Fly Pharma

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Focused oncology pipeline with Phase 3 progression on DFP-10917 in acute myeloid leukemia signals clinical traction and near-term inflection point
Early-stage company structure offers accelerated learning curve and broader responsibility scope versus large pharma hierarchies
Japan-based headquarters provides access to Asian biotech ecosystem and potentially distinct IP/regulatory pathways

Watch Out For

Zero active job openings and missing employee count data suggest company may be pre-scaling or in hiring freeze, limiting immediate opportunities
No commercial products, published data, or disclosed funding—significant execution risk and unclear financial runway for career stability
Early pipeline stage (4 Phase 1, 2 Phase 2, 1 Phase 3 trial) with limited trial diversity indicates narrow bet on small candidate pool

Generated by Claude from Delta-Fly Pharma's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Oral DFP-11207

Solid Tumors

Phase 1

Clinical Trials (1)

NCT02171221Phase I Study of Oral DFP-11207 in Solid Tumors

Phase 1

DFP-10917

Leukemia, Myeloid, Acute

Phase 1/2

Clinical Trials (1)

NCT06382168DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia

Phase 1/2